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Abstract: For many years, central dogma defined multiple sclerosis (MS) as a T cell-driven 
autoimmune disorder; however, over the past decade there has been a burgeoning recognition that 
B cells contribute to the pathogenesis of certain MS disease subtypes. B cells may contribute to 
MS pathogenesis through production of autoantibodies (or antibodies directed at foreign bodies, 
which unfortunately cross-react with self-antigens), through promotion of T cell activation via 
antigen presentation, or through production of cytokines. This review highlights evidence for 
antibody-dependent and antibody-independent B cell involvement in MS pathogenesis.
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Introduction
Multiple sclerosis (MS) is a common and progressive neurological disease that affects 
over 1 million people worldwide, with the Canadian Prairies showing among the highest 
incidence rates in the world.1 This demyelinating autoimmune disease usually presents 
in the prime of life and is associated with marked physical and cognitive disabilities 
and a shortened life span.2 Classically described as a neuroinflammatory autoimmune 
disease that targets the myelin in the brain and spinal cord, this complicated disease has 
an unknown etiology and no known cure. It presents with varying symptoms such as 
muscle fatigue, paralysis, loss of sensation/numbness, and pain, as well as emotional 
impairments such as depression and other mood disorders. The disease has diverse 
phenotypes.3 The majority of MS patients initially present with subacute attacks, 
with symptoms and signs referable to the central nervous system (CNS) – defined 
as a clinically isolated syndrome (CIS).4 When the attack is followed by a complete 
or partial remission which is then followed by another attack(s), often focused in a 
different location in the CNS and possibly of higher intensity, the disease course is 
defined as relapsing and remitting MS (RRMS).4 Patients who present with a gradually 
progressive course without a well-defined initial attack are presenting with primary 
progressive MS (PPMS).4 Secondary progressive MS (SPMS) is characterized by CIS 
or RRMS followed by progressive clinical worsening over time, generally 3 years or 
more after the onset of disease.4
The pathology of MS includes penetration of leukocytes across the blood–brain 
barrier (BBB), intrathecal production of antibodies, and neuroinflammation, which 
leads to demyelination and astrocytic and/or neuronal/axonal injury.2,5 In a recent study, 
Lucchinetti et al used immunohistochemistry to characterize demyelinating activity, 
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inflammatory infiltrates, and the presence of meningeal 
inflammation in cortical lesions from a cohort of patients with 
early-stage MS.6 They observed that cortical demyelination 
was common in the early stages of MS, that the majority 
of cortical lesions studied were positive for CD3+ T cells, 
and that a subset were positive for CD20+ B cells. Further, 
there was a strong topographic association between cortical 
demyelination and meningeal inflammation suggesting a 
direct relationship between inflammation and demyelination. 
The authors speculate that the reason why inflammatory 
cortical demyelination is not typically observed in chronic, 
progressive MS may relate to efficient clearance of cortical 
inflammation over time and thus does not preclude the pos-
sibility that inflammation may contribute to demyelination at 
its onset.6–11 Recent work highlighting how B cells contribute 
to inflammation and pathogenesis of certain MS disease 
subtypes are explored in this review.12,13
Evidence that intrathecal B cells 
contribute to MS pathogenesis
In the majority of MS patients, B cell numbers are elevated 
in the CNS.14 In an extensive histopathological study on 
actively demyelinating lesions obtained from MS patient 
biopsies and autopsies, four distinct lesion patterns were   
observed.15 Pattern II lesions, but not lesions following 
pattern I, II, or IV , were positive for B cells and they had 
prominent antibody deposition and complement components 
at sites of active myelin destruction.15 In other studies, immu-
nohistochemical analysis of brain and spinal cord sections 
revealed lymphoid follicle-like structures containing T cells, 
B cells, and plasma cells in the cerebral meninges in patients 
with SPMS, but not in patients with RRMS or PPMS.16–18 
These results suggest de novo formation and maintenance 
of ectopic lymphoid structures that contribute to increased B 
cell production in patients with active SPMS.16–18 Meningeal 
B cell follicles were found in close proximity to large subpial 
gray matter lesions and diffuse meningeal inflammation, 
which suggests that the lymphoid-like follicles or products 
produced by them negatively impacted the integrity of the 
cortical structures and contributed to gray matter corti-
cal demyelination.18,19 In a recent study, Lee-Chang et al 
determined that patients with CIS and RRMS had reduced 
transitional B cell numbers in the peripheral blood compared 
to control patients, but of the transitional B cells present, 
these cells had upregulated surface expression of integrins 
(α4 and β1).20 Further, transitional B cells were present 
in the cerebral spinal fluid (CSF) obtained from the CIS 
and RRMS patients but they were absent from the CSF of 
individuals with other inflammatory neurological disease.20 
Upregulated integrins (α4 and β1) likely assist these cells to 
cross the blood–CSF barrier. Overall, these studies suggest 
that MS patients have increased intrathecal B cells which may 
contribute to MS pathogenesis through antibody-dependent 
or antibody-independent mechanisms.
Antigen-independent mechanisms 
through which B cells may 
contribute to MS pathogenesis
Treatment with rituximab (anti-CD20 antibody, Rituxan®) – 
a humanized mouse anti-CD20 antibody which depletes 
CD20+ cells (ie, pre-B cells, immature B cells, mature B cells, 
and memory B cells, but not stem cells or plasmablasts) – has 
made it possible to discern whether B cells themselves or their 
antibody products contribute to MS pathogenesis. In various 
studies, RRMS patients receiving rituximab showed substan-
tially reduced B cell numbers in their CSF and serum, reduced 
levels of emerging inflammatory brain lesions, and reduced 
frequency of clinical attack despite evidence that antibody 
levels in the CSF were not immediately decreased, suggest-
ing that B cells contribute to pathology via an antibody-
independent mechanism.21–24 Further, a large scale clinical 
trial wherein patients diagnosed with RRMS were treated 
with ocrelizumab (a fully humanized anti-CD20 monoclonal 
antibody with decreased antibody-dependent, cell-mediated 
cytotoxic effects compared to rituximab) showed that these 
patients had reduced numbers of yearly relapses, decreased 
neuroinflammation, and decreased peripheral B cell levels 
compared with placebo control patients.25 Therefore, at least a 
subset of MS patients treated with anti-CD20 therapy showed 
improvement of disease, suggesting that B cells can promote 
pathology through antibody-independent mechanisms.26,27
Beyond their role as producers of antibodies, B cells con-
tribute to the induction, maintenance, and reactivation of CD4+ 
T cells, they act as antigen-presenting cells, they are required 
for maintenance and reactivation of memory cells, and they 
modulate T regulatory (Treg) cell function.28–37 Recently, it was 
reported that the B cell CXC chemokine ligand 13 was elevated 
in serum in RRMS patients with active MS.38 In data obtained 
from clinical trials, the majority of RRMS patients treated 
with rituximab responded with a proportional decrease in 
expression of CXC chemokine ligand 13 in the CSF, decreased 
B cells in CSF and periphery, and reduced T cells in the CSF.39 
When B cell effector cytokine responses were compared 
between MS patients and matched controls, activated B cells 
derived from MS patients exhibited decreased production of 
the downregulatory cytokine interleukin-10, a cytokine largely 
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produced by naive B cells.40 Bar-Or et al showed that activated 
B cells derived from MS patients exhibited increased expres-
sion of the proinflammatory cytokines lymphotoxin T and 
tumor necrosis factor α, two cytokines largely produced by 
memory B cells.26 When peripheral blood mononuclear cells 
were subjected to ex vivo B cell depletion, there was reduced 
T cell proliferation from the cells obtained from MS patients 
compared with those from healthy controls.26 The authors pro-
posed that the abnormal expression of B cell-derived cytokines 
mediate “bystander activation” of proinflammatory T cells 
which may precipitate new relapsing MS disease activity.26 If 
true, these findings offer a potential alternative to antibody-
dependent mechanism through which rituximab improves MS 
symptoms in a subset of patients.
Treg cells are negative regulators of immune responses to 
self- and foreign antigens and they play a critical role in main-
taining immune tolerance by suppressing pathologic immune 
responses.41 Compared to MS patients with SPMS or healthy 
controls, patients with RRMS have reduced numbers of Treg 
cells in their peripheral blood but increased numbers of Treg 
cells in the CSF, possibly in an attempt to downregulate local 
inflammation in the CNS.42,43 B cells have also been shown to 
influence Treg cell development, proliferation, and survival in 
culture.34,35 Thus, B cells may promote effector T cell activation 
while paradoxically they may dampen the adaptive immune 
response through induction of Treg cells. It may be, therefore, 
that B cells contribute to MS pathogenesis by inappropriately 
upregulating effector T cells or inappropriately decreasing Treg 
cells, required to maintain immune tolerance.
Evidence that antibodies contribute 
to MS pathogenesis
Immune components and soluble proteins such as serum 
antibodies pass through the BBB very poorly, if at all.44 
However, sera from MS patients in exacerbation were shown 
to have significantly reduced expression of the proteins 
occludin and vascular endothelial-cadherin compared to MS 
patients not in exacerbation or compared to normal controls.45 
These proteins are major components of the tight-junctions 
which help create the BBB and their decreased expression 
in MS patients may result in a more permeable BBB. An 
in vitro model of BBB serum from SPMS patients showed 
decreased transendothelial electrical resistance suggesting 
that serum from SPMS patients affects the permeability of 
this BBB model.46 With increased permeability, the brain may 
be exposed to a multitude of lymphocytes, blood proteins, and 
antibodies from which they are usually isolated.47 Because 
the BBB may be transiently semipermeable in at least some 
MS clinical disease subtypes, it is conceivable that circulating 
antibodies may enter the CNS and, if they share affinity for 
antigens found in the brain, contribute to pathology.2,5,48 
Indeed, serum levels in a patient with RRMS showed higher 
serum myelin oligodendrocyte glycoprotein (MOG) and 
myelin basic protein (MBP) antibodies in times of relapse 
relative to times of remission further indicating that the BBB 
in patients with MS may be transiently semipermeable.47
The majority of patients with MS present with elevated 
intrathecal antibody titers.14,49–51 When CSF obtained from 
patients with MS has been subjected to isoelectric   focusing, 
a technique used to separate proteins by their electrical 
charge, a pattern of oligoclonal bands becomes evident.48,52–54 
Because they have limited heterogeneity, intrathecal B cells 
undergoing clonal expansion and somatic hypermutation 
of the expressed antibody gene rearrangement are visual-
ized as oligoclonal bands.12,55,56 In contrast, serum-derived 
  antibodies are produced by a myriad of heterogeneous B 
cells and thus show a pattern of polyclonal banding upon 
  isoelectric focusing.55–57 The majority of oligoclonal bands 
are complement-activating immunoglobulin (Ig) G1   isotype.58 
Histopathology performed on pattern II demyelinating lesions 
obtained from MS patient biopsies and autopsies showed 
prominent antibody deposition and complement compo-
nents at sites of active myelin destruction.15 Other studies 
showed that patients with pattern II histopathologic lesions 
responded well to plasma exchange.59 Through magnetic 
resonance imaging and examination of CSF from patients 
in the early phases of MS, it was determined that an asso-
ciation between intrathecal antibody synthesis and cortical 
lesions was highly predictive of an earlier CIS conversion to 
MS and of higher disease activity.60 Further, in contrast with 
patients diagnosed with RRMS or PPMS, patients diagnosed 
with SPMS who responded positively to treatment with 
rituximab showed a decline in intrathecal antibody produc-
tion as well as decreased B cell numbers.61 Thus, in at least 
subsets of MS patients, antibodies likely contribute to MS 
pathogenesis.59,62–64
There is precedence that autoantibodies contribute to 
neurological pathology and disease. Although recently 
defined as pathologically distinct from MS, many clinicians 
still consider neuromyelitis optica (NMO; optic-spinal MS) 
as a part of the MS disease spectrum.65 NMO-associated IgG 
antibodies are present in the serum of 70% of patients with 
NMO.66 Patients with NMO respond positively to plasma 
exchange, which suggests that autoantibodies contribute 
to the pathogenesis of this autoimmune disease.67 Through 
a series of elegant experiments, researchers at the Mayo 
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Clinic showed that NMO-associated antibodies precipitated 
Aquaporin 4 from astrocyte cell membranes and definitively 
established that Aquaporin 4 is the target.67 Hence, because 
a pathogenic autoantibody contributes to the neuroinflam-
matory disorder NMO, it is reasonable to speculate that 
distinct pathogenic autoantibodies may contribute to other 
neuroinflammatory disorders such as MS.
Identification antibodies targets 
which contribute to MS 
pathogenesis
Foreign antigens
Previous infection with Epstein-Barr virus (EBV) – a virus 
with lifelong persistence in the host’s B cells – is an estab-
lished MS risk factor.68,69 Whether antibodies against viral 
proteins contribute to MS pathogenesis by binding to the 
viral antigen or by binding self-antigens – which share sig-
nificant morphology to the viral antigen – is currently under 
investigation. Jaquiery et al assessed EBV-specific humoral 
and cellular immune responses in the CSF of patients with 
early MS compared to persons with other inflammatory 
neurological diseases, noninflammatory neurological dis-
eases, or neurotropic herpesvirus cytomegalovirus (used 
as a control).70 They observed enriched intrathecal CD8+ 
cytotoxic T cells and increased antibody indexes for viral 
capsid antigen and EBV nuclear antigen 1 (EBNA-1), but 
not cytomegalovirus antibody indexes, in early MS as com-
pared with other inflammatory neurological diseases and 
noninflammatory neurological diseases patients.70 Further, 
in a survey of 100 subjects with CIS, RRMS, or PPMS over 
a 5-year period, all of whom had serologic evidence of pre-
vious EBV infection, patients with RRMS had significantly 
higher anti-EBNA-1 titers (a marker of the latent phase of the 
virus) and gadolinium-enhanced lesions on magnetic reso-
nance images compared with patients with PPMS or CIS.71 
In contrast, Jafari et al – who evaluated anti-EBV antibody 
response in serum and CSF from a large cohort of patients – 
determined that there was no evidence for elevated intrathecal 
anti-EBNA-1 IgG synthesis in MS patients relative to control 
patients when total IgG content of paired serum and CSF 
samples were normalized.72 Further, it was determined that 
although MS risk tended to be higher in individuals with 
high titers of neutralizing antibodies against EBV compared 
to those with low titers, this association was attenuated after 
adjustment for anti-EBNA-1 IgG antibody titres.73 Therefore, 
although there appears to be a strong association between 
prior EBV exposure and risk of MS, whether antibodies 
against viral proteins contribute to MS pathogenesis has not 
yet been definitively established.
Self-antigens
It has proven challenging to definitively identify the antibody 
targets to which pathogenic autoantibodies bind. While there 
is evidence that autoantibodies derived from MS patients 
bind lipids,54 carbohydrates,74,75 and DNA,76 the vast major-
ity of research has focused on investigating proteins which 
comprise the myelin sheath such as MBP, MOG, and pro-
teolipid protein as autoantibody targets. Elevated antibody 
titers against MBP and/or MOG have been reported in serum 
and CSF derived from MS patients77,78 and serum antibodies 
to MBP and MOG were observed in subgroups of patients 
with MS,79,80 which suggests that autoantibodies specific for 
myelin-derived proteins may contribute to MS pathogenesis. 
However, myelin-specific antibodies can also be detected in 
healthy controls suggesting that these targets are not defini-
tively predictive of disease.81,82 Further, although recombinant 
monoclonal antibodies generated from B cells obtained from 
CSF from MS patients showed reactivity to sites of degrad-
ing myelin and axons, specific reactivity to MOG, MBP, 
or proteolipid protein could not be confirmed.83–85 Thus, 
pathogenic antibodies which specifically contribute to MS 
disease remain elusive,49 and it may be beneficial to expand 
autoantibody screening beyond myelin-based proteins. CSF 
and sera from control and MS patients have been screened 
for autoantibodies using several approaches including phage 
display libraries, which are constructed using short peptides 
to mimic epitopes,86–89 a human brain complementary DNA 
expression library,90 human antigen microarrays,91,92 and 
a cell-based proteomic approach.93 Such techniques use short, 
linear amino acid segments to represent antibody binding 
sites, but these artificial targets fail to identify autoantibod-
ies whose epitopes are comprised of nonadjacent amino 
acids brought into close proximity through conformational 
folding of the antigen. Alternatively, they use recombinant 
antigens which lack posttranslational modification which 
may be critical for antibody–antigen binding. Studies focused 
on identifying pathogenic autoantibody targets, which take 
into account epitopes comprised of nonadjacent amino acids 
and/or posttranslational modifications, are needed to identify 
MS biomarkers and therapeutic approaches to prevent or 
combat MS.
Conclusion
Although the vast majority of MS patients have elevated 
intrathecal antibody levels, identification of the definitive 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
WilsonBiologics: Targets and Therapy 2012:6
antibody targets has remained elusive. Beyond their role in 
antibody production, intrathecal B cells may contribute to 
activation/reactivation of effector T cells and the modula-
tion of Treg cells, which may contribute to MS pathogenesis. 
Targeted depletion of pathogenic intrathecal plasma 
cells/B cells which both eliminate pathogenic antibody 
production and thwart inappropriate T cell responsiveness 
may serve as an effective preventative or treatment method 
in patients with MS.
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